Proper Dosage of Ketamine in Intravenous Regional Anesthesia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by University Health Network, Toronto.
Recruitment status was  Recruiting
Information provided by:
University Health Network, Toronto Identifier:
First received: September 20, 2005
Last updated: October 10, 2006
Last verified: September 2005
Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Condition Intervention
Drug: Different dosages of Ketamine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Study Start Date: January 2004
Estimated Study Completion Date: January 2005

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: 18-70
  2. Weight: 50-100 kg
  3. ASA: I, II, III
  4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

  1. Contraindication to IVRA such as sickle cell disease.
  2. Any known hypersensitivity reaction to Ketamine.
  3. History of chronic pain or regular medication with analgesics.
  4. History of opioid dependence.
  5. Drug of alcohol abuse.
  6. Psychiatric disorder.
  7. Allergy to acetaminophen or codeine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00221871

Contact: Colin McCartney, MD (416)603-5118

Canada, Ontario
University Health Network Recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Filomena Valle-Leutri, BSc    (416)603-5800 ext 2016   
Principal Investigator: Colin McCartney, MD         
Sub-Investigator: Vincent Chan, MD         
Sub-Investigator: Philip Peng, MD         
Sub-Investigator: Paul Tumber, MD         
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Colin McCartney, MD University Health Network, Toronto
  More Information Identifier: NCT00221871     History of Changes
Other Study ID Numbers: UHN02-0233-A 
Study First Received: September 20, 2005
Last Updated: October 10, 2006
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Anesthetics, Dissociative
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on April 27, 2016